Iran Breaks US Monopoly in Production of Medicine for Treatment of Precocious Puberty
A knowledge-based company in Iran will soon present its three-month slow-release drug ‘Triptorelin Pamoate’ to the country's pharmaceutical market. This medicinal product is used in the treatment of prostate cancer, precocious puberty in children, uterine diseases and some types of breast cancer.
“The production technology of this product is based on in situ-forming gels (formed at the injection spot), which has been indigenized in the country after years of academic research,” said Mohammad Taqi Fat'hi, the managing-director of the knowledge-based company.
He added that the injectable systems formed on the spot consist of two separate syringes, one containing the active pharmaceutical ingredient and the other containing a biocompatible and biodegradable polymer carrier (absorbable by the body).
“When using this drug, two syringes are connected to each other before injection, and the drug and the carrier are well mixed with the reciprocating movements of the syringes’ plunger,” Fat'hi said, adding that by injecting this liquid system into the body, the system becomes a semi-solid depot in the vicinity of interstitial water and traps the drug inside.
“This semi-solid capsule slowly provides the medicine needed by the patient in consecutive days and removes the need for frequent daily injections of medicine,” he explained.
Fat'hi said that the technical know-how to produce these types of drugs is currently monopolized by the two countries of the US and Iran.
4155/v
